disc medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. focused on the hepcidin pathway, the master regulator of iron metabolism, disc is advancing first-in-class therapies to transform the treatment of hematologic diseases.
Company profile
Ticker
IRON
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
FS Development Corp., Gemini Therapeutics, Inc. /DE
SEC CIK
Corporate docs
Subsidiaries
Disc Medicine Opco, Inc. • Disc Medicine Securities Corp. • Gemini Therapeutics Sub, Inc.. ...
IRS number
851613057
IRON stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
2 Apr 24
S-8
Registration of securities for employees
21 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
21 Mar 24
8-K
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer
26 Feb 24
8-K
Departure of Directors or Certain Officers
7 Feb 24
8-K
Regulation FD Disclosure
11 Dec 23
8-K
Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of
11 Dec 23
EFFECT
Notice of effectiveness
7 Dec 23
8-K
Entry into a Material Definitive Agreement
5 Dec 23
Latest ownership filings
4
William Richard White
15 Apr 24
4
William Jacob Savage
11 Apr 24
144
Notice of proposed sale of securities
11 Apr 24
4
Kevin Bitterman
7 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
4
Joanne Bryce
1 Mar 24
4
John D Quisel
1 Mar 24
4
Rahul Khara
1 Mar 24
4
Jonathan Yen-Wen Yu
1 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 370.66 mm | 370.66 mm | 370.66 mm | 370.66 mm | 370.66 mm | 370.66 mm |
Cash burn (monthly) | 2.35 mm | (no burn) | 6.32 mm | 6.37 mm | 2.49 mm | 5.44 mm |
Cash used (since last report) | 15.55 mm | n/a | 41.75 mm | 42.08 mm | 16.46 mm | 35.97 mm |
Cash remaining | 355.11 mm | n/a | 328.91 mm | 328.58 mm | 354.19 mm | 334.69 mm |
Runway (months of cash) | 150.9 | n/a | 52.0 | 51.6 | 142.1 | 61.5 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 100 |
Opened positions | 20 |
Closed positions | 18 |
Increased positions | 39 |
Reduced positions | 20 |
13F shares | Current |
---|---|
Total value | 931.42 bn |
Total shares | 31.28 mm |
Total puts | 59.73 k |
Total calls | 51.38 k |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
Access Industries Management | 3.35 mm | $165.35 mm |
Ai Dmi | 3.14 mm | $74.77 mm |
Atlas Venture Life Science Advisors | 2.75 mm | $128.98 bn |
Orbimed Advisors | 2.27 mm | $106.63 bn |
Bain Capital Life Sciences Opportunities III | 1.99 mm | $47.38 mm |
Atlas Venture Fund X | 1.59 mm | $86.30 mm |
Bain Capital Life Sciences Investors | 1.33 mm | $62.60 bn |
Adage Capital Partners GP, L.L.C. | 1.31 mm | $61.47 bn |
Paradigm Biocapital Advisors | 1.27 mm | $59.77 bn |
Novo Holdings A/S | 1.09 mm | $51.24 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Apr 24 | William Richard White | Common Stock | Sell | Dispose S | No | Yes | 32.1796 | 78 | 2.51 k | 0 |
11 Apr 24 | William Richard White | Common Stock | Sell | Dispose S | No | Yes | 31.7876 | 2,482 | 78.90 k | 78 |
11 Apr 24 | William Richard White | Common Stock | Option exercise | Acquire M | No | Yes | 9.86 | 804 | 7.93 k | 2,560 |
11 Apr 24 | William Richard White | Common Stock | Option exercise | Acquire M | No | Yes | 2.65 | 1,756 | 4.65 k | 1,756 |
11 Apr 24 | William Richard White | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 9.86 | 804 | 7.93 k | 3,412 |
11 Apr 24 | William Richard White | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 2.65 | 1,756 | 4.65 k | 5,268 |
10 Apr 24 | William Jacob Savage | Common Stock | Option exercise | Acquire M | No | No | 2.65 | 21,870 | 57.96 k | 43,405 |
10 Apr 24 | William Jacob Savage | Stock Option Common Stock | Option exercise | Dispose M | No | No | 2.65 | 8,777 | 23.26 k | 1,498 |
10 Apr 24 | William Jacob Savage | Stock Option Common Stock | Option exercise | Dispose M | No | No | 2.65 | 13,093 | 34.70 k | 4,233 |
5 Mar 24 | Bitterman Kevin | Common Stock | Sell | Dispose S | Yes | No | 73.5 | 26,157 | 1.92 mm | 677,503 |
News
Stifel Maintains Buy on Disc Medicine, Raises Price Target to $73
8 Apr 24
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
4 Apr 24
Morgan Stanley Maintains Equal-Weight on Disc Medicine, Lowers Price Target to $40
2 Apr 24
BMO Capital Maintains Outperform on Disc Medicine, Lowers Price Target to $50
2 Apr 24
Stifel Maintains Buy on Disc Medicine, Lowers Price Target to $71
2 Apr 24
Press releases
Attention Disc Medicine, Inc. Investors: Company Investigated by the Portnoy Law Firm
1 Apr 24
Investigation of Disc Medicine, Inc. (IRON) Announced by Holzer & Holzer, LLC
1 Apr 24
Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
6 Mar 24
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer
26 Feb 24
Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera
9 Feb 24